DarioHealth Corp

NASDAQ DRIO

Data sourced from

and

Download Data

DarioHealth Corp Operating Cash Flow To Current Liabilities 5 year CAGR for the quarter ending March 31, 2024: 5.33%

DarioHealth Corp Operating Cash Flow To Current Liabilities 5 year CAGR is 5.33% for the quarter ending March 31, 2024, a 121.19% change year over year. The operating cash flow to current liabilities ratio measures the ability of a company's operating cash flow to cover its current liabilities. It is calculated by dividing the operating cash flow by the current liabilities. This ratio indicates the company's short-term liquidity position and its ability to meet its immediate financial obligations using cash generated from its operations. A higher ratio suggests a stronger ability to cover current liabilities with operating cash flow. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

DarioHealth Corp Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2023 was -0.27, a 80.45% change year over year.
DarioHealth Corp Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2022 was -1.38, a -54.01% change year over year.
DarioHealth Corp Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2021 was -0.90, a 16.52% change year over year.
DarioHealth Corp Operating Cash Flow To Current Liabilities for the quarter ending March 31, 2020 was -1.07, a -89.13% change year over year.

NASDAQ: DRIO

DarioHealth Corp

CEO	Mr. Erez Raphael
IPO Date	Oct. 6, 2014
Location	United States
Headquarters	18 West 18th Street, New York, NY, United States, 10011
Employees	276
Sector	Healthcare
Industry	Health information services

Description

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Key trends